Archives: Calculators

About This Status Epilepticus Drug Dose Calculator

This Status Epilepticus Drug Dose Calculator turns one patient weight into stepwise emergency doses for adult convulsive status epilepticus, laid out in the order and on the clock the American Epilepsy Society (AES) 2016 algorithm uses. The phase framework and Phase 1–2 regimens follow AES 2016; ESETT 2019 supplies the comparative second-line evidence, and a 2024 Intensive Care Medicine review supplies the Phase 3 starting doses, where AES names the drugs but gives no dose. It is built for the emergency physician, intensivist, neurologist or pharmacist at the bedside of a convulsing adult, where the arithmetic is trivial but doing it correctly under pressure, in the right order and within the right minutes, is not.

The scope is deliberately narrow: convulsive status epilepticus in an adult of at least 40 kg. It does not cover children, non-convulsive status epilepticus, or maintenance dosing after the emergency, including the renal and hepatic adjustments that apply to continuing therapy rather than to a single load. What it adds beyond the algorithm is the part that is easy to forget: each drug’s single-dose cap, and the minimum infusion time its own FDA label rate ceiling forces on the dose just calculated.

Treatment Algorithm

Download this algorithm as a PDF — print or keep it on the unit.

How the Phases Work

Phase 1 (5–20 minutes): a benzodiazepine, and enough of it

Three options carry Level A evidence and the algorithm treats them as equivalent: intramuscular midazolam, intravenous lorazepam and intravenous diazepam. The choice is driven by access, not preference. IM midazolam needs no line, which is why RAMPART found seizures had stopped without rescue therapy at ED arrival in 73.4% of the IM midazolam group versus 63.4% of the IV lorazepam group. The difference was driven by how fast the drug reached the patient rather than by the drug itself: among subjects whose seizures ceased before arrival, median time to active treatment was 1.2 minutes for IM versus 4.8 for IV, while once given, IV lorazepam stopped convulsions in a median 1.6 minutes versus 3.3. Intubation was equally common (14.1% versus 14.4%). Where a line is already in, the two are equivalent. If none of the three is available, phenobarbital is one alternative at this stage and the only Level A one, though AES places it below the benzodiazepines because it is slower to give.

Phase 2 (20–40 minutes): one full second-line dose

The AES grades this phase Level U: there is no evidence-based preferred agent. ESETT, which randomised levetiracetam, fosphenytoin and valproate in benzodiazepine-refractory status, is the reason. Cessation with improvement in the level of consciousness occurred in 47%, 45% and 46% of patients, and the trial was stopped for futility because no drug was likely to prove most or least effective. Safety was comparable and no difference was significant: intubation within 60 minutes 20.0%, 26.4% and 16.8%, life-threatening hypotension 0.7%, 3.2% and 1.6%. The practical consequence is that the fastest agent to reach the patient is usually the best one, provided no contraindication applies.

Phase 3 (40–60 minutes): repeat, or anaesthesia with cEEG

Beyond one full second-line dose the evidence runs out. The algorithm allows either a repeat of second-line therapy or anaesthetic doses of thiopental, midazolam, pentobarbital or propofol, and requires continuous EEG for the anaesthetic route. This calculator deliberately produces no number here: an anaesthetic infusion is titrated to a burst-suppression or seizure-suppression target on EEG, not calculated from body weight in advance.

Where the Guideline Dose Sits Outside the US Label

Four of the seven regimens are standard of care and are not labelled uses, which matters when a pharmacist queries the order: levetiracetam (off-label on indication, dose and infusion time), valproate (indication and speed), intramuscular midazolam (no status epilepticus indication at all), and phenobarbital, whose label gives a mg/kg status epilepticus dose only for children. Fosphenytoin, lorazepam and diazepam carry status epilepticus indications, though fosphenytoin’s 1,500 mg PE cap falls below its labelled 15–20 mg PE/kg range above 100 kg. Each card states its own drug’s label position in full. None of this argues against the guideline — it is why the page prints each label’s own ceiling beside the dose.

How Current These Sources Are

The algorithm’s backbone is the AES 2016 guideline, which is ten years old but has not been superseded: no newer evidence-based treatment guideline for adult convulsive status epilepticus has been published, and the 2026 Neurocritical Care Society guideline covers neuroprognostication rather than dosing. The largest randomised trial of second-line therapy is still ESETT (2019). Where the guideline is silent — the Phase 3 anaesthetics — the doses come from the 2024 Intensive Care Medicine review, the most recent authoritative source with a dosing table. RAMPART (2012) and the Treiman VA trial (1998) are cited for their own results, which no later trial has restated. Every FDA label used here was retrieved in its current version, dated between February 2025 and August 2026, and all six cited papers were checked for errata, corrections and retractions: none has any.

Limitations

Doses are single doses on total body weight, and the algorithm’s repeat allowances are stated on each card rather than folded into the headline number. The page takes weight only: it cannot apply the dose reductions every one of these labels requires in the elderly, the debilitated and the critically ill, and it does not cover pregnancy, where phenobarbital is Category D and valproate carries a fetal-risk boxed warning. Minimum infusion times are arithmetic from each label’s maximum rate: they are floors, not recommendations. Contraindications are summarised, not exhaustive. This tool does not replace clinical judgement, local protocol, or the pharmacist.

Frequently Asked Questions (FAQ)

1. Why is lorazepam capped at 4 mg in status epilepticus?

The AES algorithm doses lorazepam at 0.1 mg/kg per dose with a maximum of 4 mg, and 0.1 mg/kg reaches 4 mg at 40 kg. Every adult therefore receives the same 4 mg. The FDA label agrees, stating a flat 4 mg for patients 18 years and older at no more than 2 mg per minute. The cap is per dose, not per episode: one repeat is part of the algorithm.

2. Is this the same as a Keppra loading dose for seizures?

Yes. Levetiracetam, sold as Keppra, is one of the three second line options, loaded at 60 mg/kg to a maximum of 4,500 mg as a single dose. This is not a labelled use: the US injection label covers levetiracetam only as adjunct therapy when oral dosing is not feasible, with a maximum recommended daily dose of 3,000 mg. The loading dose comes from ESETT and the guideline, not the package insert.

3. Which second line drug for status epilepticus is best?

None is established as better. ESETT randomised levetiracetam, fosphenytoin and valproate in benzodiazepine refractory status and found seizure cessation with improvement in the level of consciousness in 47, 45 and 46 percent. The trial was stopped for futility because no drug was likely to prove most or least effective. AES grades the choice Level U. Choose on what is stocked and drawn up fastest, on liver disease or pregnancy for valproate, and on cardiac risk for fosphenytoin.

4. When does status epilepticus need anaesthetic doses and cEEG?

The third phase begins at 40 to 60 minutes, when seizures continue after an adequate benzodiazepine and one full second line agent. AES lists two Level U options: repeat the second line therapy, or give anaesthetic doses of thiopental, midazolam, pentobarbital or propofol, all with continuous EEG monitoring. Without EEG you cannot distinguish sedation from continuing non convulsive status epilepticus, and the goal of therapy is termination of both clinical and electrical seizure activity.

5. Why does this status epilepticus calculator exclude children?

Paediatric dosing diverges exactly where this tool starts. Intramuscular midazolam is 10 mg above 40 kg but 5 mg in the 13 to 40 kg band, and the fosphenytoin label sets a weight based rate ceiling of 2 mg PE/kg/min for children instead of the adult flat ceiling. Applying adult rules to a small child would overdose the benzodiazepine, so the weight floor here is 40 kg.

Related Calculators

• Propofol Infusion Rate Calculator
• Midazolam Infusion Rate Calculator
• RSI Drug Dose Calculator
• Glasgow Coma Scale Calculator
• ICP Management Guideline

About This Vancomycin AUC Dosing Calculator

This Vancomycin AUC Dosing Calculator estimates the 24-hour area under the concentration-time curve (AUC₂₄) for adults on intermittent IV vancomycin, using the two-level first-order method the 2020 ASHP/IDSA/PIDS/SIDP consensus guideline names as the alternative to Bayesian software. It extrapolates a steady-state peak and trough to the true end-of-infusion and end-of-interval concentrations, integrates one dosing interval, scales to 24 hours, and applies the guideline’s dose-proportionality principle to suggest the total daily dose that lands the AUC in the 400–600 target.

The Formulas Explained

The elimination rate constant is the classic two-point log-linear slope (the Sawchuk–Zaske method); the interval AUC is a linear trapezoid over the infusion plus a log-linear decay area after it, as published for two-concentration AUC estimation by Pai and colleagues — the review the 2020 guideline cites for this approach, crediting Begg, Barclay, and Duffull as modified by Pai and Rodvold.

Worked example — 1,000 mg q12h over 1 h; peak 25 mg/L at 1.0 h after the end of infusion; trough 8 mg/L at 0.5 h before the next dose. Δt = 9.5 h; kₑ = ln(25/8)/9.5 = 0.1199 h⁻¹ (t½ 5.78 h); true peak 28.19, true trough 7.53 mg/L; interval AUC = 17.86 + 172.18 = 190.0; AUC₂₄ = 380 mg·h/L. To reach 400–600, the 2,000 mg/day regimen scales to roughly 2,100–3,150 mg/day — e.g., 1,250 mg q12h, then re-measure.

Clinical Interpretation & Limitations

The estimate is only as good as its inputs. The method assumes steady state — the guideline places that after the third or fourth dose — mono-exponential decay between the draws, and stable renal function, deteriorating or significantly improving alike; the guideline is explicit that the calculation will not be correct if a physiologic change such as renal dysfunction occurs during or after the sampling period. Steady state takes about five half-lives, so at the 20 to 40 hour half-lives of stable chronic kidney disease that is four to eight days, and day-2 levels do not qualify. Repeat it when the dose, the interval, or the patient changes.

The 400–600 target assumes a broth-microdilution MIC of 1 mg/L. The guideline notes that standard doses may not reach the target when the MIC is 2 mg/L — a stewardship conversation, not a reason to push the AUC past 600. The reverse move is blocked as well: below a BMD MIC of 1 mg/L the guideline does not recommend cutting the dose to hold the same ratio. Etest MICs read higher than broth microdilution and must not be plugged into this ratio uncritically.

An in-target AUC is not the whole kidney risk. The guideline names increased weight, pre-existing renal dysfunction and critical illness as host factors, and concurrent aminoglycosides, loop diuretics, amphotericin B, IV contrast, vasopressors and piperacillin/tazobactam as agents shown to raise nephrotoxicity in patients receiving vancomycin. The target does not change; the monitoring intensity should.

Administration safety is unchanged by AUC dosing: the label directs each dose to run at no more than 10 mg/min or over at least 60 minutes, whichever is longer, at no more than 5 mg/mL — so 1,000 mg needs 1.7 hours and a 3,000 mg load needs 5. In obese adults the guideline lowers loading to 20–25 mg/kg of actual body weight under the same 3,000 mg cap, and does not extend the mg/kg rule to maintenance: it computes that from a population clearance estimate and the target AUC, rarely above 4,500 mg/day, because maintenance doses set on actual body weight are themselves a route to supratherapeutic exposure.

Frequently Asked Questions (FAQ)

Related Calculators

• Creatinine Clearance Calculator (Cockcroft-Gault)
• eGFR Calculator (CKD-EPI 2021)
• Empiric Antibiotic Selector
• Bacterial Meningitis Empiric Therapy

About This Esmolol Infusion Rate Calculator

This Esmolol Infusion Rate Calculator converts an esmolol order in mcg/kg/min into a pump rate in mL/hr, and also shows the mg/hr and 24-hour totals that many charts record. The presets are the two ready-to-use strengths in the FDA label and the ASHP Standardize 4 Safety table: 10 mg/mL, supplied as the 2500 mg / 250 mL premixed bag, and 20 mg/mL, the 2000 mg / 100 mL double-strength bag. The label also supplies a 100 mg / 10 mL ready-to-use vial, but for giving a loading dose by hand-held syringe while the infusion is prepared rather than for the infusion itself. Custom mode covers locally prepared bags.

The Formulas Explained

The division by 1000 is the step that matters: the order is in micrograms and the bag is in milligrams. A 70 kg adult at 100 mcg/kg/min receives 7000 mcg/min, which is 420 mg/hr and runs at 42.0 mL/hr from a 10 mg/mL bag — or 21.0 mL/hr from the 20 mg/mL double-strength bag. The loading dose is a weight-based amount rather than a rate: 500 mcg/kg is 35 mg in the same patient, given over one minute.

Clinical Interpretation & Limitations

Esmolol is a cardioselective beta-1 blocker with an elimination half-life of about 9 minutes. That is its whole point: beta-blockade can be started in a patient who might not tolerate it, and withdrawn within minutes if they do not. The label’s own indications are supraventricular tachycardia or non-compensatory sinus tachycardia, and perioperative tachycardia and hypertension.

Hypotension is the dose-limiting effect, not bradycardia. It leads the label’s adverse-reaction table: asymptomatic hypotension 25%, symptomatic hypotension 12% (hyperhidrosis, dizziness). The footnote is the part worth carrying to the bedside — hypotension resolved during the infusion in 63% of patients, and in 80% of the remainder within 30 minutes of stopping. Most episodes settle without stopping the drug at all. Because the effect is dose-related the first move is to cut the rate; the label then directs that symptomatic hypotension be supported with intravenous fluids or a vasopressor, so volume is not to be withheld.

Beyond the labelled indications

Rate control in atrial fibrillation or flutter is a labelled indication, not an off-label one. Section 1.1 indicates esmolol for rapid control of ventricular rate in atrial fibrillation or flutter in perioperative, postoperative or other emergent circumstances. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline lists it for acute rate control at 500 mcg/kg over 1 minute, then 50–300 mcg/kg/min — an upper figure that exceeds the label’s own 200 mcg/kg/min rate-control ceiling.

The genuinely off-label use is heart-rate control in septic shock. The 2013 single-centre open-label trial reported 28-day mortality of 49.4% with esmolol versus 80.5% with standard care, but the control-arm mortality was extreme and the design was phase 2. A 2025 meta-analysis of 8 randomised trials found no significant mortality reduction (RR 0.84, 95% CI 0.68–1.02) and called its own result not robust. There is also a labelling conflict: most of these patients are on norepinephrine, which the label names among the agents that should preclude using esmolol for rate control. Treat it as unsettled; this ladder is the label’s, not a sepsis protocol.

Limitations

• Adults only. Paediatric pharmacokinetics differ — a shorter half-life and higher clearance in newborns and infants, and reported post-coarctectomy requirements averaging around 700 mcg/kg/min, well outside this table.
• The colour bands are label ranges, not outcome-validated targets. No trial ties a band to survival.
• The label limits maintenance infusions to up to 48 hours; longer courses are outside its evidence.
• “No dosage adjustment needed” is narrower than it sounds. Esmolol is hydrolysed by red-cell esterases and the label requires no adjustment in hepatic impairment, but its renal statement is bounded: no adjustment for a maintenance infusion of 150 mcg/kg over 4 hours, with no information on rates above 150 mcg/kg or infusions longer than 4 hours. The renally cleared acid metabolite has a half-life about 12-fold longer in end-stage renal disease, and the label warns of potentially life-threatening hyperkalaemia in haemodialysis patients.
• Weight entry stops at 199 kg, the house limit across these calculators.

Frequently Asked Questions (FAQ)

1. What rate does an esmolol infusion run at?

The FDA label’s step-wise table starts maintenance at 50 mcg/kg/min and moves through 100, 150 and 200 mcg/kg/min, titrating at intervals of at least 4 minutes. The effective maintenance range is 50 to 200 mcg/kg/min, although the label notes doses as low as 25 mcg/kg/min have been adequate. At 70 kg on a 10 mg/mL bag, 100 mcg/kg/min is 42 mL/hr.

2. Is the esmolol loading dose required?

No. The label calls it optional and states that without loading doses a continuous infusion reaches steady state in about 30 minutes. For gradual control it is 500 mcg/kg over one minute; for immediate perioperative control the label instead gives 1 mg/kg over 30 seconds followed by 150 mcg/kg/min. Additional loading doses may be repeated between steps.

3. Why is the esmolol bag labelled in mg/mL when the order is in mcg/kg/min?

Because esmolol is one of the few infusions where the concentration unit and the dosing unit differ, which the ASHP Standardize 4 Safety table flags explicitly. A 10 mg/mL bag is 10,000 mcg/mL, so a bag read as 10 mcg/mL would be a thousandfold error. Confirm the bag strength before programming, and remember 1 mg is 1000 mcg.

4. Can esmolol be run above 200 mcg/kg/min?

Not for rate control. The label states that maintenance doses above 200 mcg/kg/min are not recommended because they provide little additional heart-rate lowering and adverse reactions increase. For hypertension the label allows 250 to 300 mcg/kg/min, and states the safety of doses above 300 mcg/kg/min has not been studied.

5. How quickly does esmolol wear off after it is stopped?

Its elimination half-life is approximately 9 minutes, which is why it is chosen when beta-blockade may need to be withdrawn quickly. The label states hypotension usually reverses within 30 minutes of reducing or stopping the infusion, and that stopping the infusion is the first step in managing toxicity.

Related Calculators

Before switching between these agents, read the label’s two constraints. Esmolol is contraindicated with intravenous cardiodepressant calcium-channel antagonists given in close proximity — while the cardiac effects of the other are still present — and the label records fatal cardiac arrests with esmolol plus intravenous verapamil. When transitioning, it sets a specific taper: thirty minutes after the first dose of the alternative drug, halve the esmolol infusion rate, then stop it after the second dose if control holds for an hour.

• Diltiazem Infusion Rate Calculator
• Amiodarone Infusion Rate Calculator
• Vasopressor Equivalent Dose Calculator
• Norepinephrine Infusion Rate Calculator
• AFib with RVR Treatment Guideline

About This Vasopressor Equivalent Dose Calculator

This Vasopressor Equivalent Dose Calculator converts several concurrently running vasopressors into a single norepinephrine equivalent dose (NEE) in mcg/kg/min, applying the updated equation of Kotani and colleagues (Critical Care 2023;27:29) as corrected in 2025, and showing what each agent contributes so the total can be audited rather than trusted blindly. Six agents are covered; the formula’s other five (terlipressin, metaraminol, methylene blue, hydroxocobalamin, midodrine) are omitted as unavailable in most units or, for methylene blue, assigned a factor the authors call arbitrary.

The Formulas Explained

Norepinephrine, epinephrine and phenylephrine are entered in mcg/kg/min, so a flat order is divided by weight first: Dose (mcg/kg/min) = Dose (mcg/min) ÷ Weight (kg). Dopamine has no flat-rate form in this formula and is always per kilogram. An 80 kg patient on norepinephrine 0.1 mcg/kg/min, dopamine 5 mcg/kg/min, vasopressin 0.03 units/min and angiotensin II 20 ng/kg/min has an NEE of 0.1 + 0.05 + 0.075 + 0.05 = 0.275 mcg/kg/min. Multiplied by weight that is 22 mcg/min — the same score written in another unit for charting, not a norepinephrine dose that could be hung in place of these four infusions.

Each coefficient traces to a specific comparison. Epinephrine is assigned 1 because two randomised trials found the dose needed to reach the same mean arterial pressure target was similar. Dopamine is 1/100 from SOAP II, where its dose ran consistently 100 times that of norepinephrine. Vasopressin is 2.5 read directly off VANISH, where 0.06 units/min spared 0.15 mcg/kg/min (0.15 ÷ 0.06 = 2.5); VASST is consistent but only near 100 kg, because it reported norepinephrine as a flat mcg/min rate — which is why this term is weight-blind and credits a 45 kg patient the same 0.075. Angiotensin II is 0.0025 from ATHOS-3, where 20 ng/kg/min lowered the norepinephrine requirement by a mean 0.05 mcg/kg/min compared with placebo.

Clinical Interpretation & Limitations

NEE exists because modern shock is treated with combinations. Once a patient is on norepinephrine plus vasopressin plus angiotensin II, no single infusion rate describes the support being given, and eligibility criteria written as “norepinephrine above X” stop working. One scale makes severity comparable across patients and centres — including where norepinephrine itself is unavailable.

What the number is not. It is not a target, not a titration guide, and not a conversion table for switching agents at the bedside. The equivalences were derived from group means in trials with different populations, targets and eras; an individual patient’s response to phenylephrine is not 0.06 of their response to norepinephrine. Equal NEE does not mean equal patient — because vasopressors differ in inotropic effect and interact with vascular tone, volume state and contractility, the authors note that “similar MAPs may correspond to very different hemodynamic profile despite comparable NEE”. An NEE of 0.4 built from epinephrine is a different patient from an NEE of 0.4 built from phenylephrine.

It under-states some patients badly. The formula counts vasoconstrictors only. A patient on veno-arterial ECMO with high-dose inotropes and low-dose norepinephrine has a low NEE that misrepresents the true intensity of haemodynamic support, and the authors say NEE must be used and interpreted cautiously in that population. Inotropes such as dobutamine and milrinone are not part of the equation at all.

Which formula produced a published NEE

Reported NEE values are not comparable unless the formula is stated. Older equations differ structurally: VASST 2008 and Gutsche 2017 mix flat mcg/min for norepinephrine with weight-based mcg/kg/min for dopamine in one line, and the published vasopressin factor ranges from 2.5 to 500 (Ralib 2013), partly a units difference and partly outright disagreement — Brown 2013 uses 5 where this formula uses 2.5. Both are tabulated in Table 1 of the source paper. Cite the equation with any NEE you quote.

Limitations

• Adults only, and the source trials are not homogeneous: the phenylephrine factor rests on one small non-randomised septic-shock study and one randomised trial in patients under spinal anaesthesia, and published phenylephrine ratios span 1.1 to 16.3. It is the least secure term here.
• No severity bands are shown. The source paper defines no threshold for high-dose or refractory shock, so this page assigns none; any cut-off you have seen comes from a local protocol or an individual trial, not from this equation.
• Five agents in the published formula are omitted here; no formula covers steroids or mechanical support comparably. Weight entry stops at 199 kg, the house limit across these calculators.
• The base-versus-salt ambiguity is unresolved internationally and can move the result twofold. The offset is systematic, so trends within one patient or unit stay valid; comparison against a published NEE does not.

Frequently Asked Questions (FAQ)

1. What is a norepinephrine equivalent dose?

Norepinephrine equivalence (NEE) expresses several vasopressors running at once as the single norepinephrine dose of comparable potency, so total vasopressor support can be stated as one number. Studies use it as an eligibility criterion and an outcome measure. It describes exposure, not weanability, and its ability to predict outcome has not yet been validated.

2. Which equivalence formula does this calculator use, and why does that matter?

It uses the updated NEE equation of Kotani and colleagues (Critical Care 2023;27:29), as corrected in 2025. Published formulas disagree: the phenylephrine coefficient is 0.06 here but 1/10 in the 2021 Goradia scoping review, and the two angiotensin II factors differ fourfold even after the units are aligned. Always record which formula an NEE came from.

3. Why does the vasopressin contribution not change with body weight?

Vasopressin is ordered as a fixed rate in units per minute, not per kilogram, so the published coefficient of 2.5 multiplies units/min directly. At 0.03 units/min the contribution is 0.075 mcg/kg/min for every patient. Every other agent, angiotensin II included, is normalised per kilogram first, so weight moves those terms but not this one.

4. Is there an NEE threshold that defines high-dose or refractory shock?

Not in this formula’s source. The paper proposing the equation sets out no cut-off, and this calculator deliberately shows no colour bands and no risk categories, because assigning one would mean inventing a threshold no trial validated. Local protocols and individual trials do define high-dose support, but not as part of this equation.

5. Does the norepinephrine base or salt formulation change the result?

It can, by up to twofold. The formula’s authors report that norepinephrine base is not marketed anywhere, that every product is a salt, and that salts seem on average half as potent as the base — a difference pharmacists would call one of dilution rather than potency. They state it is unknown which basis published scores mean.

Related Calculators

• Norepinephrine Infusion Rate Calculator
• Vasopressin Infusion Rate Calculator
• Epinephrine Infusion Rate Calculator
• Phenylephrine Infusion Rate Calculator
• Dopamine Infusion Rate Calculator
• Esmolol Infusion Rate Calculator

About This Phenylephrine Infusion Rate Calculator

This Phenylephrine Infusion Rate Calculator converts a continuous phenylephrine order into a pump rate. The drug is prescribed in two units — the ASHP and Fresenius-label convention is weight-based mcg/kg/min, while the Baxter label writes flat mcg/min. The tool accepts either and displays both.

Presets follow the ASHP Standardize 4 Safety adult standards: 80 and 400 mcg/mL for fluid restriction. Custom mode covers other preparations, including the label’s own 10 mg in 500 mL (20 mcg/mL).

The Formulas Explained

In weight-based mode the per-minute dose comes first: Dose (mcg/min) = Dose (mcg/kg/min) × Weight (kg) — 1.0 mcg/kg/min at 70 kg is 70 mcg/min, which runs at 52.5 mL/hr from the 80 mcg/mL bag and 10.5 mL/hr at 400 mcg/mL. In flat mode the rate does not depend on weight — 35 mcg/min from an 80 mcg/mL bag is 26.25 mL/hr at any weight; weight drives only the equivalent column.

Clinical Interpretation & Limitations

Phenylephrine is a selective α1-adrenergic agonist: it vasoconstricts without direct cardiac stimulation, so blood pressure rises while baroreceptor reflexes slow the heart. Both labels indicate it only for hypotension primarily from vasodilation. It is avoided when cardiac output is marginal, because rising afterload plus reflex bradycardia can drop output further even as the MAP target is met.

It is not first-line in septic shock. Norepinephrine is, at an initial MAP target of 65 mmHg. The first randomized head-to-head comparison, in 32 septic shock patients, found no differences in cardiopulmonary performance, oxygen transport or regional hemodynamics — hemodynamic similarity, not outcome equivalence. During the 2011 US norepinephrine shortage it became the most used alternative, and admission during shortage quarters carried higher in-hospital mortality (39.6% vs 35.9%; adjusted OR 1.15, 95% CI 1.01–1.30) — the exposure measured was shortage, not phenylephrine itself. Both labels also warn it can increase the need for renal replacement therapy in septic shock — monitor renal function.

Obstetric anesthesia is where much of the labelled evidence sits: 26 of the 42 perioperative studies behind the vial label were in low-risk pregnant women under neuraxial anesthesia for caesarean delivery. An international consensus statement on vasopressors for spinal hypotension at caesarean section (Anaesthesia 2018;73:71–92) sets out regimens outside this calculator’s ladder. One labelled interaction governs that setting: oxytocic drugs potentiate the pressor effect, with the potential for hemorrhagic stroke.

Starting and maintenance dose

The Fresenius vial label gives two weight-based ranges: 0.5–1.4 mcg/kg/min for hypotension during anesthesia and 0.5–6 mcg/kg/min in vasodilatory (including septic) shock, titrated to the blood pressure goal — adding that doses above 6 mcg/kg/min show no significant incremental increase in blood pressure. The Baxter label writes the same drug flat, for anesthesia only: 10–35 mcg/min, not to exceed 200 mcg/min. The two are not numerically interchangeable — at 80 kg the flat maximum of 200 mcg/min is 2.5 mcg/kg/min, well below the weight-based shock ceiling of 6. Both ranges start at 0.5, so the lowest rows serve either indication.

Limitations

• Adults only. Rows and presets come from the adult label ranges and ASHP table.
• The colour bands are label ranges, not outcome-validated targets — no trial ties a dose band to survival.
• No automatic adjustment for organ dysfunction — cirrhosis blunts the response (more may be needed), ESRD increases it (start lower). No account of line dead space at low rates, nor of carrier volume at the top: 6 mcg/kg/min at 80 mcg/mL in a 70 kg adult is 315 mL/hr.

Frequently Asked Questions (FAQ)

1. Should a phenylephrine infusion be dosed in mcg/kg/min or mcg/min?

The ASHP Standardize 4 Safety adult standard dosing unit for phenylephrine is weight-based mcg/kg/min, which is this calculator’s default. Flat mcg/min ordering is still common and is the convention printed on the Baxter FDA label (anesthesia only), so both units are always shown together. At 80 kg, 35 mcg/min is about 0.44 mcg/kg/min.

2. What are the standard phenylephrine infusion concentrations?

The ASHP adult standards are 80 mcg/mL (e.g. 20 mg in 250 mL, the default here) and 400 mcg/mL (e.g. 100 mg in 250 mL, for fluid restriction). The vial label’s own preparation is 10 mg in 500 mL, giving 20 mcg/mL. The 10 mg/mL vial is 10,000 mcg/mL and must always be diluted.

3. When is phenylephrine used instead of norepinephrine?

Norepinephrine is the first-line vasopressor for septic shock. Phenylephrine is reached for when β stimulation is unwanted, most often in severe tachyarrhythmias, and it became the most used alternative during the 2011 US norepinephrine shortage — when mortality at affected hospitals was higher, an association not proof of cause. The first randomized head-to-head trial, in 32 patients, found no hemodynamic differences.

4. Why does the heart rate fall on a phenylephrine infusion?

Phenylephrine is a selective alpha-1 agonist without direct cardiac stimulation, so the rise in blood pressure triggers a baroreceptor reflex that slows the heart. Mild slowing is expected, but both labels warn of severe bradycardia with decreased cardiac output. It is a poor choice when output is already low, since output may fall further as afterload rises.

5. Can phenylephrine run through a peripheral line?

Dilute phenylephrine is often started peripherally while central access is obtained, but it is a vasoconstrictor: extravasation can cause local tissue ischemia and necrosis. Use a vein in or proximal to the antecubital fossa, keep the peripheral period short, check the site often, and follow local policy.

Related Calculators

• Norepinephrine Infusion Rate Calculator
• Vasopressin Infusion Rate Calculator
• Epinephrine Infusion Rate Calculator
• Vasopressor Equivalent Dose Calculator
• Post-Cardiac Arrest Care Guideline

About This Insulin Infusion Rate Calculator

This Insulin Infusion Rate Calculator converts a continuous IV regular insulin order into a pump rate. Adult ICUs run insulin for two jobs — hyperglycemic crises (DKA and HHS), ordered weight-based in units/kg/hr, and routine glucose control, where nurse-driven protocols titrate a flat units/hr rate. The tool accepts either unit and shows both, with the mL/hr rate and the 24-hour total.

The preset follows the ASHP Standardize 4 Safety standard concentration for glycemic-control infusions: 1 unit/mL. ASHP lists a second standard, 16 units/mL, solely for high-dose insulin therapy in calcium-channel-blocker or beta-blocker overdose — a separate order set this tool does not convert. Insulin is a high-alert medication: the converter does not recommend a rate, and the guideline content restated here does not replace your institution’s approved order set. The potassium and hypoglycemia gates are hard stops, not background reading.

The Formulas Explained

To convert units/kg/hr to mL/hr, this insulin infusion rate calculator takes the hourly dose first: Dose (units/hr) = Dose (units/kg/hr) × Weight (kg). At 1 unit/mL the final division changes nothing — 0.1 units/kg/hr in an 80 kg patient is 8 units/hr and the pump runs at 8.00 mL/hr. In a 0.5 units/mL bag the same order runs at 16.00 mL/hr, which is why the concentration sits directly above the rate table.

The bolus row uses 0.1 units/kg — optional in the 2024 consensus, considered when a delay in obtaining venous access is anticipated, and it may be given IV or IM. A single dose drawn from a U-100 vial, not an hourly rate, and not used in HHS.

Clinical Interpretation & Limitations

In DKA the infusion is a fixed-rate protocol, not a titration to a glucose target. Resolution is biochemical — blood ketones below 0.6 mmol/L with venous pH ≥7.3 or bicarbonate ≥18 mmol/L — not a glucose number, which is why the rate is reduced rather than stopped once dextrose goes up. The expected 50–75 mg/dL per hour fall is a 2009 consensus figure the 2024 report does not restate. HHS differs: fluids carry more of the treatment, insulin starts at 0.05 units/kg/hr when there is no significant ketonemia, and the glucose decline is held to no more than 90–120 mg/dL per hour. The full pathway is in our DKA & HHS treatment guideline below.

For general ICU glucose control the evidence question is the target, not the drug. NICE-SUGAR randomized 6,104 critically ill adults and found higher 90-day mortality with an 81–108 mg/dL target (27.5% vs 24.9%) than with a conventional target of 180 mg/dL or less; severe hypoglycemia was far more common in the intensive arm (6.8% vs 0.5%), though the trial did not establish that it caused the excess deaths. Nurse-driven column protocols implement the titration; this insulin infusion rate calculator converts the ordered rate and reproduces no titration table.

Starting and maintenance dose

Start at 0.1 units/kg/hr for DKA — 7 units/hr at 70 kg — with no bolus required. For non-DKA control there is no single guideline starting rate; nurse-driven protocols derive the initial rate from the current glucose and an insulin-sensitivity factor, then titrate to the 140–180 mg/dL band. The rows in the table are conversion steps, not a normal range: requirements vary several-fold with steroids, vasopressors, nutrition, obesity and sepsis, and rates above the top row are routine in insulin-resistant patients.

Potassium, dextrose and the checkpoints that matter

• K+ below 3.5 mmol/L: hold insulin and replace potassium (about 10 mmol/hr) until K+ is at least 3.5.
• K+ 3.5–5.0 mmol/L: start insulin and add 20–30 mmol of potassium per liter of fluid, targeting 4–5 mmol/L.
• K+ above 5.0 mmol/L: start insulin without added potassium; recheck in 2 hours.
• Glucose below 250 mg/dL in DKA: add 5–10% dextrose and reduce to 0.05 units/kg/hr rather than stopping.
• Euglycemic DKA: about 10% of DKA presents with glucose below 200 mg/dL, and SGLT2 inhibitors now account for most of those cases. Dextrose is started alongside the saline from the outset rather than added later, and the diagnosis rests on ketones and acidosis, never on the glucose number.
• Glucose below 70 mg/dL: treat immediately with IV dextrose and recheck. In non-DKA control, hold the infusion until glucose recovers; in DKA, raise the dextrose and reduce the rate rather than stopping, because the ketoacidosis is still being treated.

Organ dysfunction and special situations

• Renal impairment: insulin is partly cleared by the kidney, so requirements fall and hypoglycemia risk rises in AKI, CKD and dialysis.
• Concentration and stability: the Humulin R label supports IV use at 0.1–1 unit/mL in 0.9% sodium chloride, and a prepared bag is stable for 48 hours refrigerated and then up to 48 more at room temperature. Outside that range is a preparation question, not a rate question.
• Rising requirements: corticosteroids, catecholamines and advancing nutrition push requirements up; resolving sepsis, a steroid taper, and interrupted feeds or a lapsed TPN bag pull them down — the classic setup for overnight hypoglycemia.
• Stopping: the label gives a mean half-life of about 20 minutes after a 0.1 unit/kg IV dose and about an hour after 0.2 unit/kg, so circulating insulin is gone within roughly an hour of stopping the pump. In DKA, overlap the first basal subcutaneous dose 1–2 hours before discontinuation.

Limitations

• Adults only, and IV regular insulin only — not subcutaneous regimens, U-500, or the rapid-acting-analog pathway some units use for mild-to-moderate DKA.
• The hyperkalemia order — insulin with dextrose — is a single push, not an infusion, and is not computed here.
• No titration advice: the tool shows what the ordered rate delivers, never when to change it.
• The 24-h column is a projection of one rate held for a day, not the insulin actually delivered — do not use it to size the subcutaneous transition dose. It counts the infusion only; boluses are additive.
• Weight is entered as your local protocol defines it. The consensus states the fixed rate per kg without specifying a weight basis; most protocols use actual body weight.

Frequently Asked Questions (FAQ)

1. Why does units/hr equal mL/hr on a standard insulin infusion?

The ASHP adult standard concentration for a regular insulin infusion is 1 unit/mL, usually 100 units in 100 mL of saline. At that concentration the pump rate in mL/hr is identical to the dose in units/hr — a 4 units/hr order runs at 4.00 mL/hr. The equality breaks at any other concentration; the custom mode covers those.

2. What insulin infusion rate is used for DKA?

The 2024 ADA/EASD consensus recommends fixed-rate IV regular insulin at 0.1 units/kg/hr; an initial 0.1 units/kg bolus is optional, mainly when venous access is expected to be delayed. Below 250 mg/dL, dextrose is added and the rate reduced to 0.05 units/kg/hr until the ketoacidosis resolves. The familiar 50–75 mg/dL per hour fall is a 2009 figure the 2024 report does not restate.

3. Why must potassium be checked before starting an insulin infusion?

Insulin drives potassium into cells, so a patient already below 3.5 mmol/L can develop dangerous hypokalemia and arrhythmias within hours. Below 3.5 mmol/L the infusion is held while potassium is replaced; at 3.5–5.0 mmol/L potassium is added to each liter of fluid as insulin runs. Total-body potassium is depleted in DKA even when the first value looks normal or high.

4. What glucose target does an ICU insulin infusion aim for?

For most critically ill adults the target is 140–180 mg/dL, started once glucose is persistently 180 mg/dL or higher. NICE-SUGAR found that a tighter 81–108 mg/dL target increased 90-day mortality versus a conventional target of 180 mg/dL or less, with severe hypoglycemia far more common in the tight arm. DKA is the exception: the rate there is driven by ketone clearance, not by this target.

5. How is an IV insulin infusion stopped safely?

The label gives a mean half-life of about 20 minutes after a 0.1 unit/kg IV dose, so an abrupt stop leaves almost no circulating insulin — in DKA that causes rebound ketoacidosis. Give the first long-acting basal subcutaneous dose 1–2 hours before the pump stops, once the crisis has resolved and the patient can eat. The full transition is in our DKA and HHS guideline.

Related Calculators

• DKA & HHS Treatment Guideline
• Anion Gap Calculator
• Serum Osmolality & Osmolar Gap Calculator
• ABG Analyzer
• HOMA-IR Calculator

About This Fentanyl Infusion Rate Calculator

This Fentanyl Infusion Rate Calculator converts a continuous fentanyl order into a pump rate. Fentanyl is the opioid infusion most adult ICUs run, yet it is prescribed in two units — some services write a flat fentanyl drip rate in mcg/hr, others a weight-based rate in mcg/kg/hr. The tool accepts either and displays both, with the mL/hr rate and 24-hour total for each step of the ladder.

Presets follow the ASHP Standardize 4 Safety adult continuous infusion standards: 10 mcg/mL (conventionally 2500 mcg in 250 mL) and 50 mcg/mL for fluid restriction, matching undiluted fentanyl citrate injection. A custom mode covers other preparations.

The Formulas Explained

To convert fentanyl mcg/kg/hr to mL/hr the hourly dose is taken first: Dose (mcg/hr) = Dose (mcg/kg/hr) × Weight (kg). In flat mcg/hr mode the pump rate does not depend on weight at all — 50 mcg/hr from a 10 mcg/mL bag is 5.00 mL/hr at 60 kg and at 120 kg. Weight drives only the equivalent column and the bolus.

The bolus row uses 0.35–0.5 mcg/kg, the intermittent-dosing entry from the 2013 SCCM pharmacology table. In that source it is an alternative to a continuous infusion, so when given on top of a running drip the two must be added. The ubiquitous 50–100 mcg ICU bolus is not a critical care guideline figure — it comes from the premedication section of the fentanyl citrate label.

Clinical Interpretation & Limitations

The ladder describes observed practice, not a recommended range. In a 2025 cohort of 238 ventilated adults (144 on fentanyl) the average hourly dose was 55 mcg/hr (IQR 39–75) with a cumulative 4241 mcg (IQR 1817–8146) during mechanical ventilation, in fentanyl equivalents, and no difference in 28-day ventilator-free survival against hydromorphone. The colour bands key to that interquartile range. A rate above roughly 150 mcg/hr — twice the observed upper quartile — should prompt reassessment of the analgesic strategy rather than further escalation.

PADIS 2018 makes a Good Practice Statement that pain be assessed routinely and treated before a sedative is considered, with BPS and CPOT the most valid tools where self-report is impossible; vital signs are explicitly not valid pain indicators. Opioid-sparing adjuncts with PADIS recommendations include acetaminophen, nefopam, low-dose ketamine post-surgically, and — the only strong recommendation in the pain section — a neuropathic agent alongside opioids for neuropathic pain. Note the guideline’s ketamine dose is per minute, a sixty-fold difference from the unit used here.

Starting and maintenance dose

The only infusion range published in a critical care guideline is 0.7–10 mcg/kg/hr, from the opioid pharmacology table of the 2013 PAD guideline; the same row is the source of the 0.35–0.5 mcg/kg every 30–60 minutes intermittent dose used by the bolus field above. Start at the lower bound, 0.7 mcg/kg/hr — at 78 kg, the median weight of the 2025 ventilated cohort, that is 55 mcg/hr, which is that cohort’s average hourly dose exactly: the guideline floor and observed practice agree on where an infusion begins. The maintenance range is then whatever the pain score requires within roughly 39–75 mcg/hr, the observed interquartile range that the colour bands in the table above key to. The ceiling is not a target: 10 mcg/kg/hr is about 780 mcg/hr at the same weight, roughly ten times the observed upper quartile, and that table has not been reaffirmed in the guidelines that followed it.

Organ dysfunction and obesity

• Renal: norfentanyl is described as inactive on animal data, which is why fentanyl is preferred to morphine. Clearance still falls with worsening uraemia — expect a slower offset rather than no adjustment.
• Hepatic and shock: a high-extraction drug, so hepatic blood flow dominates over enzyme inhibition. CYP3A4 inhibitors still raise exposure — azoles, protease inhibitors, clarithromycin and erythromycin (not azithromycin), amiodarone, diltiazem or verapamil; rifampin, carbamazepine and phenytoin lower it.
• Serotonergic drugs: the label warns of serotonin syndrome and advises against use with an MAOI or within 14 days of stopping one. Linezolid and methylene blue are the ICU-specific culprits.
• Obesity: the dosing weight is unresolved — pharmacokinetic work derived a non-linear pharmacokinetic mass, other reviews favour lean or adjusted weight, none from ICU infusions. Total body weight overestimates requirements; a flat mcg/hr order avoids this for the infusion, though not for the weight-based bolus.
• ECMO, CRRT, hypothermia: circuit sequestration is large ex vivo but in-vivo requirements are unpredictable; haemofilter clearance is small relative to total clearance; clearance is reduced during cooling. Titrate to score rather than adjusting reflexively.

Chest wall rigidity

Classically a phenomenon of rapid high-dose administration — the 50% incidence figure comes from volunteers given 15 mcg/kg at 150 mcg/min, an induction load a maintenance infusion does not reach. It is nonetheless reported during continuous ICU infusion, so consider it on sudden loss of ventilator compliance. Stop or substitute the fentanyl and secure ventilation; naloxone treats the cause and neuromuscular blockade does not, so titrate naloxone in 0.04 mg increments and expect to repeat it, since its effect is shorter than fentanyl’s.

Limitations

• Adults only. Labelling does not establish safety below 2 years and specifies reduced doses for ages 2–12; the ASHP adult standards are scoped to ≥50 kg.
• Continuous infusion for ICU analgesia is off-label in the US. The label’s 2, 2–20 and 20–50 mcg/kg figures are total procedural doses — never hourly rates — which is why they are not shown beside infusion rates.
• No automatic adjustment for organ dysfunction, and no account of line dead space. The 24-hour total counts the infusion only; boluses are additive.
• No drip-to-patch conversion and no morphine milligram equivalent: neither is validated for an intravenous fentanyl infusion in critically ill patients.

Frequently Asked Questions (FAQ)

1. Should a fentanyl infusion be dosed in mcg/hr or mcg/kg/hr?

The ASHP Standardize 4 Safety adult standard dosing unit for fentanyl is flat mcg/hour, which is this calculator’s default. No guideline specifies which body weight a mcg/kg/hr order should use, and total body weight overestimates requirements in obesity. Both units are shown together so an order written in one is never read as the other.

2. What are the standard fentanyl infusion concentrations?

The ASHP adult standards are 10 mcg/mL (default, typically 2500 mcg in 250 mL) and 50 mcg/mL (alternative for fluid restriction, matching undiluted fentanyl citrate injection). Vial strength is expressed as fentanyl base, so no salt-conversion factor applies. At 50 mcg/mL routine rates fall to roughly 0.5–3 mL/hr, which can be smaller than the dead space of an extension set.

3. What fentanyl infusion rates are actually used in adult ICUs?

In 144 ventilated adults receiving fentanyl, the average hourly dose was 55 mcg/hr (IQR 39–75) with a cumulative 4241 mcg (IQR 1817–8146) during mechanical ventilation, in fentanyl equivalents. The widely quoted 0.7–10 mcg/kg/hr range is a 2013 background pharmacology table that was never reaffirmed; its ceiling is about 700 mcg/hr at 70 kg.

4. Is fentanyl safe in kidney failure?

It is preferred over morphine because morphine accumulates active glucuronide metabolites, not because fentanyl is unaffected. Clearance still falls with worsening uraemia, so expect a slower offset and titrate to a validated pain score rather than assuming no adjustment is needed.

5. Can a fentanyl infusion be converted to a transdermal patch?

No validated conversion exists for critically ill patients and this calculator does not compute one. The published basis is a small chronic-cancer-pain series using a 1:1 mcg/hr ratio. Transdermal absorption is unpredictable with oedema, vasopressors and fever, the patch cannot be titrated for about three days, and the DURAGESIC conversion table contains no intravenous fentanyl row.

Related Calculators

• Remifentanil Infusion Rate Calculator
• Dexmedetomidine Infusion Rate Calculator
• Ketamine Infusion Rate Calculator
• Opioid Equivalent Dose Calculator
• ICU Sedation Protocol

About This Levosimendan Infusion Rate Calculator

This Levosimendan Infusion Rate Calculator converts a weight-based dose into a pump rate in mL/hr for the two standard dilutions of levosimendan (Simdax) 2.5 mg/mL concentrate. It returns the optional loading dose, the maintenance rate across the full licensed titration range, and the 24-hour volume for each step so that the number of 500 mL bags required for a complete course is immediately apparent.

Levosimendan occupies an unusual position among inotropes. It is approved in many European and Latin American countries but is not approved by the US FDA, and it does not hold a UK marketing authorisation — in the UK it is obtained as an unlicensed import — so it is absent from most North American dosing references. It is also mechanistically distinct: rather than raising intracellular calcium through β-receptors or phosphodiesterase inhibition, it sensitises cardiac troponin C to calcium already present, producing inotropy without a meaningful rise in myocardial oxygen demand, while opening ATP-sensitive potassium channels to produce arterial, coronary and venous vasodilation.

The Formulas Explained

Loading Dose (Optional)

The product information permits 6–12 mcg/kg over 10 minutes, and specifies the lower 6 mcg/kg dose for patients already receiving intravenous vasodilators or inotropes. This tool defaults to no loading dose, which reflects both the hypotension risk and the design of every large contemporary trial.

Continuous Infusion Rate

The two supplied dilutions are 0.025 mg/mL (25 mcg/mL, made by adding 5 mL of concentrate to 500 mL of 5% glucose) and 0.05 mg/mL (50 mcg/mL, made by adding 10 mL to 500 mL of 5% glucose). Outputs from this levosimendan dosing calculator have been cross-checked against the manufacturer’s published weight-based infusion tables across the 40–120 kg range for both dilutions.

Clinical Interpretation & Limitations

Start at 0.1 mcg/kg/min and reassess the patient during the loading dose or within 30–60 minutes of any adjustment. If the response is excessive — hypotension or tachycardia — reduce to 0.05 mcg/kg/min or stop. If the initial dose is tolerated and a greater haemodynamic effect is needed, increase to 0.2 mcg/kg/min. The recommended duration is 24 hours; no tolerance or rebound has been observed on discontinuation.

The clinically distinctive feature is persistence. Because the active metabolite OR-1896 has a half-life of 75–80 hours and reaches peak plasma concentration roughly 2 days after the infusion is stopped, haemodynamic effects continue long after the pump is disconnected. Blood pressure effects generally last 3–4 days and heart rate effects 7–9 days. Non-invasive monitoring for at least 3 days after the end of the infusion is recommended, extending to at least 5 days in mild-to-moderate renal or hepatic impairment, where metabolite concentrations rise further; some institutional protocols continue ECG, blood pressure and electrolyte monitoring for 7–10 days in these patients.

Administer the continuous infusion through central venous access using an infusion pump, ideally with medication-error-reduction software enabled. Avoid administering levosimendan in lines where other drugs or fluids may be bolused or flushed, as an inadvertent bolus can precipitate hypotension. Because the drug is a potent vasodilator, concomitant nitrates such as isosorbide mononitrate significantly potentiate orthostatic hypotension and should prompt closer haemodynamic observation.

Limitations

• This Levosimendan Infusion Rate Calculator assumes an adult patient and the two standard dilutions above. It performs no renal or hepatic dose adjustment, because the product information specifies none — instead, severe impairment is an outright contraindication.
• Evidence outside acutely decompensated heart failure is not supportive. LEVO-CTS, CHEETAH and LICORN each failed to demonstrate benefit in cardiac surgery, and the 2026 Surviving Sepsis Campaign guideline recommends against use in septic shock. Perioperative and shock use remains off-label.
• The concentrate contains a high proportion of ethanol as an excipient, which is relevant in patients with alcohol dependence, hepatic disease or epilepsy.
• Hypotension is the dominant adverse effect, and baseline systolic pressure below 100 mmHg or diastolic below 60 mmHg was identified in a post-hoc analysis of REVIVE II as a factor increasing mortality risk. Clinical judgement about haemodynamic suitability sits outside this tool.

Frequently Asked Questions (FAQ)

1. Should I give a levosimendan loading dose?

Often no. The product information permits an optional 6–12 mcg/kg bolus over 10 minutes, and specifies the lower 6 mcg/kg dose when the patient is already receiving intravenous vasodilators or inotropes. However, LICORN, LEVO-CTS and CHEETAH all omitted the bolus entirely; the LICORN investigators stated this was done to avoid excessive vasodilation in a fragile population. Omitting it is the safer default in hypotensive patients.

2. How is levosimendan diluted for infusion?

Add 5 mL of the 2.5 mg/mL concentrate to 500 mL of 5% glucose for a 0.025 mg/mL infusion, or 10 mL to 500 mL of 5% glucose for 0.05 mg/mL. Only 5% glucose is specified as the diluent. The diluted solution should not be stored or infused beyond 24 hours, and the concentrate is for single use only.

3. How long should the infusion run, and what happens after it stops?

Twenty-four hours is the recommended duration in acute decompensation of severe chronic heart failure. Effects then persist for days through the active metabolite OR-1896: blood pressure effects for 3–4 days and heart rate effects for 7–9 days. Non-invasive monitoring for at least 3 days after the infusion ends is recommended, or at least 5 days with mild-to-moderate renal or hepatic impairment.

4. What is the maximum infusion rate?

0.2 mcg/kg/min is the maximum within the recommended maintenance range of 0.05–0.2 mcg/kg/min. Rates at or above 0.4 mcg/kg/min, and infusions beyond 24 hours, increase heart rate and are sometimes associated with prolongation of the QTc interval. This Levosimendan Infusion Rate Calculator therefore stops at 0.2 mcg/kg/min.

5. Can levosimendan be used after cardiac surgery or in septic shock?

Both are outside the licensed indication. In cardiac surgery, LEVO-CTS, CHEETAH and LICORN were all neutral for their primary endpoints. For septic shock, the 2026 Surviving Sepsis Campaign guideline recommends against levosimendan. The manufacturer also notes that use in cardiogenic shock has not been studied.

6. Who should not receive levosimendan?

It is contraindicated in creatinine clearance below 30 mL/min, severe hepatic impairment, severe hypotension with tachycardia, significant mechanical obstruction affecting ventricular filling or outflow, a history of Torsades de Pointes, and known hypersensitivity. It is not recommended under 18 years of age. Low serum potassium and severe hypovolaemia should be corrected before starting.

Related Calculators

• Milrinone Infusion Rate Calculator
• Dobutamine Infusion Rate Calculator
• Norepinephrine Infusion Rate Calculator
• Creatinine Clearance Calculator
• Epinephrine Infusion Rate Calculator

About This Serum Osmolality & Osmolar Gap Calculator

The Serum Osmolality & Osmolar Gap Calculator estimates serum osmolality from the major measured osmoles — sodium, glucose and urea (BUN) — with an optional term for measured ethanol. When a laboratory-measured osmolality is also entered, the tool computes the osmolar gap (measured minus calculated). A widened gap suggests the presence of unmeasured osmoles and, in the right clinical context, is an important early clue to toxic-alcohol poisoning (methanol, ethylene glycol) and other low-molecular-weight substances such as isopropanol, acetone, mannitol or propylene glycol.

This calculator uses conventional (US) units: sodium in mEq/L and glucose, BUN and ethanol in mg/dL. An SI-unit toggle is a planned future enhancement and is intentionally not built here, because hard-coding mixed unit conversions is a common source of error. In SI units the calculated osmolality is computed differently: Calculated osmolality (mOsm/kg) = 2 × Na (mmol/L) + glucose (mmol/L) + urea (mmol/L) [+ ethanol (mmol/L)], where each solute is already in mmol/L and is added directly (no division). Note that urea (mmol/L) = BUN (mg/dL) ÷ 2.8.

The Formula Explained

The most widely used US formula sums twice the sodium (to account for accompanying anions) plus glucose and urea converted from mg/dL to mmol/L. The optional ethanol term uses the Purssell coefficient of 3.7.

Sodium is in mEq/L; glucose, BUN and ethanol are in mg/dL. The divisors convert mg/dL to mmol/L using each substance’s molecular weight (glucose 180, urea-nitrogen 2.8, ethanol 3.7). The ethanol term is included only when a measured ethanol value is entered.

Clinical Interpretation & Limitations

Calculated osmolality is normally about 275–295 mOsm/kg (values below 275 are low and above 295 are high). The osmolar gap is interpreted as follows:

• Gap < 10 (commonly cited normal range): within the usual reference range, but this does not exclude a toxic alcohol — the range is wide and a small or late ingestion can sit here.
• Gap 10–20 (mildly elevated): non-specific. Causes include early or late toxic-alcohol poisoning, ketoacidosis, lactic acidosis, renal failure, ethanol, mannitol and propylene glycol.
• Gap > 20–25 (significant): strongly suggests methanol or ethylene glycol, especially with a high anion gap metabolic acidosis — consider empiric fomepizole and toxicology consultation. A gap > 50 is almost always a toxic alcohol, mannitol or propylene glycol.

A classic pattern is a high osmolar gap combined with a high anion gap metabolic acidosis; early in toxic-alcohol poisoning the osmolar gap is elevated with a normal anion gap, and this reverses as the alcohol is metabolized.

Limitations

• A normal osmolar gap does not exclude toxic-alcohol poisoning — sensitivity is poor. If clinical suspicion is high, treat (fomepizole) and consult toxicology or poison control rather than waiting for the gap.
• Screening, not diagnosis: definitive diagnosis requires direct serum concentrations of the suspected alcohol.
• Formula-dependence: different published formulas yield slightly different calculated values; keep the formula and the measurement method consistent.
• Measurement method matters: a vapor-pressure osmometer does not capture volatile alcohols and will underestimate the gap. Use freezing-point depression osmometry.
• Ethanol coefficient: 3.7 is the standard divisor; using a larger coefficient under-corrects for ethanol and can leave a falsely elevated residual gap.
• Pseudohyponatremia: severe hyperlipidemia or hyperproteinemia can distort the measured sodium and the calculated osmolality.

Frequently Asked Questions (FAQ)

1. What does the osmolar gap detect?

The difference between measured and calculated osmolality reflects unmeasured osmoles — methanol, ethylene glycol, isopropanol, acetone, mannitol or propylene glycol. A large gap raises concern for one of these, but it cannot tell you which one is present.

2. If the gap is under 10, is the patient in the clear?

Only partly. The normal range is wide and an individual baseline is usually unknown, so early or late presentations can have a normal gap. A normal osmolar gap must not be used on its own to rule out a toxic alcohol.

3. Why is an ethanol term included?

Ethanol is the most common cause of an elevated osmolar gap. If you do not account for it, its contribution inflates the gap; subtracting the ethanol term (ethanol ÷ 3.7) means any residual gap better reflects more dangerous osmoles.

4. What is the difference between osmolality and osmolarity?

The calculated value approximates osmolarity (mOsm/L), while the laboratory measures osmolality (mOsm/kg) by freezing-point depression. By convention the osmolar gap is measured osmolality minus calculated osmolarity, with the units treated as interchangeable for this estimate.

5. Does a high gap confirm methanol or ethylene glycol poisoning?

No. A high gap raises suspicion and, with a high anion gap acidosis, may justify empiric fomepizole and toxicology consultation, but confirmation requires direct serum drug concentrations.

About This Winters’ Formula Calculator

The Winters’ Formula Calculator determines the expected arterial PaCO₂ for a patient with a primary metabolic acid-base disorder. In a primary metabolic acidosis, the lungs compensate by increasing ventilation to blow off CO₂; in a primary metabolic alkalosis, they hypoventilate to retain CO₂. Winters’ formula quantifies how much respiratory compensation should occur. By comparing the patient’s measured PaCO₂ with the expected PaCO₂, the clinician can judge whether compensation is appropriate or whether a second, concomitant respiratory disorder is masking or adding to the picture — a key step in identifying mixed acid-base disturbances.

The Formula Explained

For a primary metabolic acidosis, the classic Winters’ equation predicts the expected PaCO₂ from the serum bicarbonate, with an accepted variation of plus or minus 2 mmHg:

For a primary metabolic alkalosis, a separate expectation is used (Berend 2014); some references instead cite “+20” or “ΔPaCO₂ ≈ 0.7 × ΔHCO₃⁻ (±5)”:

HCO₃⁻ is entered in mEq/L (equivalent to mmol/L) and PaCO₂ is in mmHg; no unit conversion is required. This calculator applies the constants for the selected mode automatically.

Clinical Interpretation & Limitations

Once a measured PaCO₂ is entered, the result is interpreted against the expected range for the active mode:

• Within the expected range: respiratory compensation is appropriate for the primary metabolic disorder. No separate respiratory disorder is identified.
• Below the expected range: a concomitant respiratory alkalosis is present. Classic triggers include salicylate toxicity, sepsis, and liver failure.
• Above the expected range: a concomitant respiratory acidosis is present, signalling inadequate ventilation (respiratory fatigue, or a CNS or airway problem) — often a medical emergency. In metabolic alkalosis specifically, compensatory hypoventilation is limited by the hypoxic drive, so a PaCO₂ above roughly 55 mmHg points to a true respiratory acidosis rather than expected compensation.

Example: A patient in DKA has an HCO₃⁻ of 12 mEq/L. Expected PaCO₂ = 1.5 × 12 + 8 = 26 mmHg (range 24–28). A measured PaCO₂ of 26 mmHg confirms appropriate respiratory compensation; a value of 34 mmHg would indicate a superimposed respiratory acidosis.

Limitations

• Mode matters: the acidosis and alkalosis constants are different and must not be interchanged. Confirm the primary disorder before reading the result, and use the mode selector deliberately.
• Primary disorder must be established first: the formula assumes you have already identified a primary metabolic acidosis or alkalosis from the pH, HCO₃⁻ and clinical context.
• Steady state: compensation takes time to develop; in acute, rapidly evolving disturbances the steady-state assumption may not hold.
• Physiologic ceiling on alkalosis compensation: hypoventilation is limited by hypoxic drive, so very high PaCO₂ values are unlikely to be purely compensatory.
• Not a complete assessment: the formula does not evaluate oxygenation or the underlying cause. Interpret alongside the full ABG and the anion gap.

Frequently Asked Questions (FAQ)

1. What is this calculator used for?

It computes the expected PaCO₂ in a primary metabolic acidosis (and, in alkalosis mode, a metabolic alkalosis) so you can detect a second, concomitant respiratory disorder.

2. What if the measured PaCO₂ is higher than expected?

A measured PaCO₂ above the expected range indicates a concomitant respiratory acidosis — ventilation is inadequate, which can be an emergency.

3. What if the measured PaCO₂ is lower than expected?

A measured PaCO₂ below the expected range indicates a concomitant respiratory alkalosis, classically from salicylate toxicity, sepsis, or liver failure.

4. Can I use this for metabolic alkalosis?

Not with Winters’ formula itself. Metabolic alkalosis uses a separate expectation (0.7 × HCO₃⁻ + 21, ±2). Select the alkalosis mode and the calculator switches to the correct constants.

5. Why the plus or minus 2?

The ±2 mmHg reflects normal individual variation in compensation. A measured PaCO₂ anywhere within that range counts as appropriate compensation.

6. Does compensation normalize the pH?

No. Compensation does not fully correct the pH. A normal pH alongside an abnormal HCO₃⁻ and PaCO₂ suggests a mixed acid-base disorder.